0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
2101 Views 
0 Saved
0 Vote 1 Contributor2101 Views 0 SavedYou might also be interested in
Be thankful if you are lactose intolerant because it could save you from certain cancers including breast cancer. Some researchers from Sweden said in 2014 that people who are lactose intolerant might be less likely to develop lung, breast and ovarian cancers. Low dairy consumption seems to reduce t....
Most breast lumps women feel - 8 out of 10 - aren't cancer. It's more common for them to be a cyst (a sac) or a fibroadenoma (an abnormal growth that's not cancer). Some lumps come and go during a woman's menstrual cycle. When you feel a lump in your breast, it's understandable to be concerned. B....
Hello, please describe your problem in detail, then only we'll be able to provide you treatment costs. You can call us on +91-8010994994 and talk to our medical expert.
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.